Avexxin As

TRONDHEIM, Norway, January 10, 2011 - Avexxin AS, a Norwegian pharma company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the closure of a financing round enabling the company to take its lead compound against psoriasis through early clinical development.